Literature DB >> 1858528

Modulation by interferon alpha of the decreased natural killer activity in patients with glioblastoma.

P Lapeña1, C Isasi, J Vaquero, R Martinez, M Alvarez-Mon.   

Abstract

It is known that natural killer (NK) cells are involved in immunosurveillance against tumours. This study examines the NK activity of mononuclear cells (MNC) from the peripheral blood of patients with glioblastoma. The cytotoxic inducer effect of interferon-alpha (IFN-alpha) upon these MNC has also been studied. A marked decrease in NK activity mediated by MNC from these patients was found. This functional defected in MNC is not due to a decrease in phenotypically defined NK cells. After long-term (5-day) incubation with IFN-alpha, MNC from 5 out of 14 patients showed strong lytic activity against NK-sensitive target cells. In this system, IFN-alpha failed to induce cytotoxic activity against NK-resistant target cells in MNC from all the patients studied. This in vitro induction of cytotoxic activity in MNC from some patients with glioblastoma by IFN-alpha suggests a potential immunotherapeutic use of the lymphokine in these subjects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1858528     DOI: 10.1007/bf01403004

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  13 in total

1.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  Clinical signification of natural killer activity in B-cell chronic lymphocytic leukemia.

Authors:  M Alvarez-Mon; J Casas; R Laguna; J Jordá; A Durantez
Journal:  Eur J Haematol       Date:  1987-03       Impact factor: 2.997

3.  Analysis by a single cell cytotoxicity assay of natural killer (NK) cells frequencies among human large granular lymphocytes and of the effects of interferon on their activity.

Authors:  T Timonen; J R Ortaldo; R B Herberman
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

4.  Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma.

Authors:  J Vaquero; R Martínez; S Oya; S Coca; L Barbolla; J Ramiro; F G Salazar
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

5.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

Authors:  M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

6.  Regulation of natural killer cell function by glass-adherent cells in patients with primary intracranial malignancies.

Authors:  D P Braun; R D Penn; J E Harris
Journal:  Neurosurgery       Date:  1984-07       Impact factor: 4.654

7.  Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder.

Authors:  J Carballido; M Alvarez-Mon; O J Solovera; L Menéndez-Ondina; A Durántez
Journal:  J Urol       Date:  1990-01       Impact factor: 7.450

8.  Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease.

Authors:  A S Kadish; A T Doyle; E H Steinhauer; N A Ghossein
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

9.  Direct evidence for the role of LGL in the inhibition of experimental tumor metastases.

Authors:  T Barlozzari; J Leonhardt; R H Wiltrout; R B Herberman; C W Reynolds
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

10.  Co-expression of Mac-1 and p150,95 on CD5+ B cells. Structural and functional characterization in a human chronic lymphocytic leukemia.

Authors:  A De la Hera; M Alvarez-Mon; F Sanchez-Madrid; C Martinez; A Durantez
Journal:  Eur J Immunol       Date:  1988-07       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.